MK-677 Ibutamoren

MK-677

Ibutamoren · MK-0677 · Nutrobal · Oral Ghrelin Mimetic

"Not technically a peptide — but mechanistically the most accessible GH secretagogue available. A once-daily oral pill that raises GH and IGF-1 for 24 hours by mimicking ghrelin at the pituitary. The Merck Phase 2 data is real. So is the insulin resistance risk."

Type

Non-peptide ghrelin mimetic · oral GHS

Key trial

Nass 2008 (Ann Int Med): +1.1kg FFM at 12 months

GH/IGF-1 effect

Restores to young-adult levels in 60-81yo subjects

Key risk

Insulin resistance · fasting glucose +5mg/dL

WADA

Prohibited at all times

Protocol summary

Community dose

12.5–25 mg/day oral

Class

Small molecule (NOT peptide)

Mechanism

Ghrelin receptor agonist

Clinical development

Halted (heart failure signal)

How we read the evidence

Oral non-peptide ghrelin receptor agonist · sustained GH/IGF-1 elevation · Adunsky 2011 hip fracture trial halted early due to heart failure signal · NOT a peptide · WADA-banned · clinical development discontinued

Animal evidence

Substantial preclinical foundation. Important: MK-677 (ibutamoren mesylate, L-163,191) is a non-peptidyl small-molecule ghrelin receptor agonist — not a peptide. Included on this platform because it occupies the same GH-axis space as several covered peptides and is widely used alongside research peptides. Mechanism: oral, BBB-penetrant agonist of GHSR-1a (the ghrelin receptor), producing sustained elevation of pulsatile GH secretion and IGF-1 levels, with feedback by IGF-1 limiting excess GH production. Originally developed at Merck in the 1990s (Chapman et al. 1996, design paper for L-163,191). Animal models — diet-induced catabolism, ageing, sleep architecture, body composition — supported the original Merck development pathway.

Community & clinical practice

Standard community use is 12.5–25 mg oral once daily, typically before bed (matching the natural nocturnal GH peak and capitalising on the sleep-architecture effects). Long-term continuous use is the standard model — unlike GHRPs, MK-677 doesn't show the same receptor-desensitisation pattern. Cycle length 8–24 weeks then break, primarily because of the predictable side effects (water retention, increased appetite, insulin resistance). Side effects are dose-related and well-characterised: appetite stimulation (most users), lower-extremity edema (significant proportion, more pronounced in elderly), fasting glucose elevation (~5 mg/dL in Nass trial), GH-mediated insulin resistance worsening glucose tolerance especially in prediabetic/elderly populations.

Human trial data

Substantial Phase 2 evidence base — and a notable safety signal that ended development. Nass et al. 2008 (Annals of Internal Medicine, PMC 2757071) — 2-year RCT modified-crossover, 25 mg/day oral MK-677 vs placebo (2:1) in healthy older adults. Results: sustained pulsatile GH amplitude and IGF-1 elevation to young-adult levels, fat-free mass increase 1.6 kg vs placebo (perspective: average lifetime FFM loss is ~5.5 kg), increased intracellular water, femoral neck BMD declined at 12 months (consistent with increased bone remodelling). Bach et al. 2004 (JAGS) — initial hip fracture trial suggested muscle strength and functional performance improvement. Adunsky et al. 2011 (Arch Gerontol Geriatr) — Phase 2b multicentre hip fracture trial halted prematurely due to higher heart failure rate in MK-677 group (6.5% vs 1.7% placebo) — improvements in stair climbing power and gait speed observed but truncated by safety stop. Campbell et al. 2018 — haemodialysis IGF-1 study. The CHF signal appears concentrated in elderly patients with underlying cardiac vulnerability.

Regulatory status

Not approved by any regulatory agency. Merck pursued the compound through Phase 2 for elderly muscle wasting and frailty indications then discontinued development — the heart failure signal in the Adunsky trial was a major contributing factor. WADA-banned for tested athletes (Section S2 — peptide hormones, growth factors, related substances and mimetics). Sold widely as a research chemical via online vendors, often inaccurately marketed alongside peptides despite being a small molecule. Long-term cardiovascular safety in healthy adults outside Merck's elderly populations has not been characterised.

Convergence

MK-677 has substantial Phase 2 evidence — Nass 2008 demonstrated genuine sustained GH/IGF-1 elevation with measurable body composition effects, and the mechanism is well-validated. But Merck halted development specifically because of a heart failure signal in the Adunsky 2011 hip fracture trial (6.5% vs 1.7% placebo CHF rate triggered early termination), and that finding has not been adequately followed up in younger healthy populations. Pep IQ flags this honestly: this is a small molecule (not a peptide), with real efficacy data AND a real safety signal that ended pharma development. Standard community protocol: 12.5–25 mg oral nightly, 8–24 weeks then break. Members considering MK-677 should be aware that the GH/IGF-1 elevation comes paired with predictable side effects (appetite, edema, glucose) and a documented CHF signal in elderly trial populations — younger users may face lower absolute risk but the evidence to confirm that safety profile does not exist.

Community-reported

12.5–25 mg/day oral · bedtime

Monitor glucose monthly · insulin resistance risk

Origin & Background

The oral GH secretagogue — Merck's most studied

MK-677 (ibutamoren mesylate) was developed by Merck Research Laboratories as an orally active, non-peptide ghrelin receptor agonist. Unlike GHRP peptides which require injection, MK-677 is a small molecule derived from GHRP-6 and spiroindanylpiperidine that can be taken as a once-daily pill. It activates GHS-R1a (the ghrelin receptor) in the hypothalamus and pituitary, stimulating pulsatile GH release without requiring injection.

Merck ran a substantial clinical programme, culminating in the landmark Nass et al. (2008) Annals of Internal Medicine study — a 2-year, double-blind, randomised, placebo-controlled trial of 65 healthy older adults (aged 60-81) at 25mg/day. The results were encouraging: GH and IGF-1 were restored to young-adult levels, fat-free mass increased 1.1kg vs a 0.5kg decline in placebo, and the compound was generally well-tolerated. Development was ultimately discontinued by Merck — not due to safety failures but due to business reasons and the complexity of demonstrating functional benefits beyond biomarker improvement.

Despite non-approval, MK-677 became one of the most widely used "research chemicals" in the GH optimisation community, largely because of its oral convenience, affordable cost, and the availability of legitimate Merck clinical data to cite. It is also one of the most frequently adulterated products in the grey market, with FDA testing revealing hidden ibutamoren in products marketed for other purposes.

Science & Mechanism

Pulsatile GH restoration — without injection

Mechanism of Action

GHS-R1a agonism: MK-677 activates the same ghrelin receptor as the injectable GHRPs — triggering L-type Ca²⁺ channel opening, intracellular calcium increase, and protein kinase C activation → GH pulse release from pituitary somatotrophs.

24-hour GH elevation: The Chapman (1996) study showed 25mg MK-677 increased mean 24-hour GH concentration by 97% and IGF-1 by 88% at 4 weeks. Unlike injectable GHRPs (half-life minutes), the oral bioavailability and extended pharmacokinetics of MK-677 maintain elevated GH throughout the day — a fundamentally different pharmacological profile.

Preservation of pulsatility: Unlike exogenous GH injections (which create a pharmacological bolus and suppress endogenous production), MK-677 amplifies the existing pulsatile GH pattern — increasing peak height without changing peak frequency. This is considered more physiological than continuous GH exposure.

IGF-1 restoration: In older adults with age-related GH decline, MK-677 25mg/day restored IGF-1 to levels normal for young adults (116-358 μg/L range) within weeks. This is the most consistently demonstrated and clinically relevant effect.

Appetite stimulation (orexigenic effect): By activating GHS-R1a in the hypothalamic feeding centres — the same pathway as endogenous ghrelin — MK-677 stimulates appetite. This is a direct pharmacological consequence and is consistently reported in clinical trials. The appetite effect is one of the reasons Merck explored it for sarcopenia and hip fracture recovery, where stimulating appetite is therapeutically desired.

The 12-month Nass 2008 trial results deserve careful reading: FFM +1.1kg (significant), body cell mass +0.8kg (significant), but no improvement in strength or function despite higher FFM. The FFM gain likely contains a substantial intracellular water component rather than purely contractile muscle. Fasting blood glucose increased ~5mg/dL and insulin sensitivity declined — clinically meaningful metabolic signals requiring monitoring. Cortisol increased 47 nmol/L. The hip fracture recovery trial showed improvement in stair-climbing power and gait speed — a functional outcome more clinically compelling than the body composition data.

Benefits & Evidence

What the data shows

📈

GH and IGF-1 restoration

Nass 2008 (n=65): restored 24h mean GH and IGF-1 to young-adult range in 60-81yo subjects. Chapman 1996: +97% GH, +88% IGF-1 at 4 weeks (25mg). The most consistently demonstrated and well-quantified effect across all MK-677 trials.

● Strong — multiple Phase 2 RCTs

💪

Fat-free mass preservation

Nass 2008: +1.1kg FFM vs -0.5kg placebo over 12 months in older adults (P<0.001). Hip fracture trial: stair-climbing power and gait speed improved. Note: strength did not improve significantly in the 12-month trial; part of the FFM gain is intracellular water not contractile muscle.

● Moderate — RCT data but functional gains modest

🦴

Bone turnover markers

Bone resorption markers increased 26%, bone formation markers elevated at 8 weeks (obese young males, Wuster study). MK-677 + alendronate mitigated alendronate-induced suppression of bone formation. Bone mineral density effects less consistent across studies.

● Moderate — biomarkers consistent · BMD variable

💤

Sleep quality

GH-coupled slow-wave sleep enhancement. Consistently the most reliably reported subjective benefit by community users. Enhanced REM sleep quality and vivid dreams frequently noted. Underpinned by the same mechanism as GH's natural sleep-promoting effects.

● Moderate — mechanism strong · objective RCT data limited

Safety First

Risks & considerations

Moderate

Insulin resistance and glucose elevation — Nass 2008: fasting glucose +5mg/dL, insulin sensitivity declined. This effect is consistent across trials. Monitor fasting glucose every 4-6 weeks. People with pre-diabetes or metabolic syndrome should use extreme caution.

Moderate

Appetite stimulation — 20-40% of users report significant hunger increase, especially first 4-6 weeks. Can impair weight management goals if not actively managed. Habituation occurs but may not fully resolve.

Moderate

Fluid retention and oedema — lower extremity oedema in 5-10% of users. Mild and typically resolves on discontinuation.

Serious

Potential heart failure risk in susceptible individuals — one Merck trial was stopped early due to congestive heart failure concerns. This risk is likely confined to patients with pre-existing cardiac dysfunction. Contraindicated in anyone with LV dysfunction or cardiac failure history.

Serious

Adulteration risk — FDA 2024 found hidden ibutamoren in products marketed for other purposes. Grey-market MK-677 cannot be verified for purity or dosing accuracy. This is the most practical safety concern for community users.